EPIOMIC EPIDEMIOLOGY SERIES: RETINAL DETACHMENT FORECAST IN 18 MAJOR MARKETS 2018–2028

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Retinal Detachment in 18 Major Markets

Retinal detachment (RD) is a condition in which the neurosensory retina (NSR), a layer of the retina composed of light-sensitive visual cells, separates from the retinal pigment epithelium (RPE). It is a serious condition potentially causing blindness, and one of the few ocular conditions requiring immediate medical intervention.

This report provides the current incident population for RD across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current incidence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, subtypes of the condition, as well as several features of RD patients have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of RD include:
• High myopia
• Inflammatory diseases (e.g., Vogt–Koyanagi–Harada syndrome, Behçet’s disease)
• Malignant and non-malignant retinal pathologies
• Age-related macular degeneration
• Choroidal neoplasms and metastases
• Glaucoma
• End-stage renal disease
• Sickle-cell disease
• Diabetes mellitus
• Bacterial and viral infections / nematode infestations

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
• Ability to quantify patient populations in global RD market to target the development of future products, pricing strategies and launch plans.
• Further insight into the incidence of the subdivided types of RD and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the incident population of RD patients.
• Identification of RD patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of RD patients.